The Pan American Health Organization (PAHO) announces a new agreement with Gilead Sciences to facilitate access to lenacapavir, a preventive HIV medication, in 14 countries in the region. This treatment, administered twice a year, aims to reduce new infections, which amount to approximately 140,000 per year. PAHO will support countries in integrating this medication into their health programs while promoting local production in Brazil.